miR-625 reverses multidrug resistance in gastric cancer cells by directly targeting ALDH1A1

References

• Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–2664. doi:10.1016/S0140-6736(16)30354-327156933
   PubMed Web of Science ®Google Scholar
• Wagner AD, Syn NLX, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064.
   PubMed Web of Science ®Google Scholar
• Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J. 2011;17(2):89–95. doi:10.1097/PPO.0b013e318212dd3d21427552
   PubMed Web of Science ®Google Scholar
• Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010;6(4):527–537. doi:10.2217/fon.10.2120373867
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314. doi:10.1146/annurev-pathol-012513-10471524079833
   PubMed Web of Science ®Google Scholar
• Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372–379. doi:10.1002/ijc.2350118449891
   PubMed Web of Science ®Google Scholar
• Wang F, Li T, Zhang B, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013;434(3):688–694. doi:10.1016/j.bbrc.2013.04.01023603256
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett. 2013;587(18):3069–3075. doi:10.1016/j.febslet.2013.06.05823932924
   PubMed Web of Science ®Google Scholar
• Shang Y, Zhang Z, Liu Z, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33(25):3267–3276. doi:10.1038/onc.2013.29723893241
   PubMed Web of Science ®Google Scholar
• Wang M, Li C, Nie H, et al. Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett. 2012;586(16):2382–2388. doi:10.1016/j.febslet.2012.05.05022677169
   PubMed Web of Science ®Google Scholar
• Zheng G, Liu X, Han F. [Establishment and characterization of doxorubicin-resistant BGC-823/DOX of human gastric cancer cell line]. Zhonghua Wai Ke Za Zhi. 1997;35(5):262–264.10374555
   PubMedGoogle Scholar
• Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179. doi:10.1093/nar/gni17816314309
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• Crowley LC, Marfell BJ, Scott AP, et al. Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry. Cold Spring Harb Protoc. 2016;2016(11):pdb.prot087288. doi:10.1101/pdb.prot087288
   Google Scholar
• Zhu W, Shan X, Wang T, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127(11):2520–2529. doi:10.1002/ijc.2526020162574
   PubMed Web of Science ®Google Scholar
• Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013;85(9):1219–1226. doi:10.18632/oncotarget.238823435357
   PubMed Web of Science ®Google Scholar
• Pan ST, Li ZL, He ZX, et al. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016;43(8):723–737. doi:10.1111/1440-1681.1258127097837
   PubMed Web of Science ®Google Scholar
• Dolka I, Krol M, Sapierzynski R. Evaluation of apoptosis-associated protein (Bcl-2, Bax, cleaved caspase-3 and p53) expression in canine mammary tumors: an immunohistochemical and prognostic study. Res Vet Sci. 2016;105:124–133. doi:10.1016/j.rvsc.2016.02.00427033920
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature Rev Mol Cell Biol. 2014;15(1):49–63. doi:10.1038/nrm372224355989
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469. doi:10.1016/j.molmed.2014.06.00525027972
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. doi:10.1016/j.cell.2004.12.03515652477
   PubMed Web of Science ®Google Scholar
• Li X-S, Xu Q, Fu X, et al. ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. BMC Cancer. 2014;14(1):705. doi:10.1186/1471-2407-14-70525253129
   PubMedGoogle Scholar
• Januchowski R, Wojtowicz K, Zabel M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother. 2013;67(7):669–680. doi:10.1016/j.biopha.2013.04.00523721823
   PubMed Web of Science ®Google Scholar
• Garrido M, Fonseca PJ, Vieitez JM, Frunza M, Lacave AJ. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. Expert Rev Anticancer Ther. 2014;14(8):887–900. doi:10.1586/14737140.2014.91519424953238
   PubMed Web of Science ®Google Scholar
• Fan K, Fan D, Cheng LF, Li C. Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res. 2000;20(6C):4809–4814.11205224
   PubMed Web of Science ®Google Scholar
• Dehghanzadeh R, Jadidi-Niaragh F, Gharibi T, Yousefi M. MicroRNA-induced drug resistance in gastric cancer. Biomed Pharmacother. 2015;74:191–199. doi:10.1016/j.biopha.2015.08.00926349984
   PubMed Web of Science ®Google Scholar
• Riquelme I, Letelier P, Riffo-Campos AL, Brebi P, Roa J. Emerging role of miRNAs in the drug resistance of gastric cancer. Int J Mol Sci. 2016;17(3):424. doi:10.3390/ijms1703042427011182
   PubMed Web of Science ®Google Scholar
• Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347(2):159–166. doi:10.1016/j.canlet.2014.03.01324657660
   PubMed Web of Science ®Google Scholar
• Shin VY, Chu KM. miRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014;20(30):10432–10439. doi:10.3748/wjg.v20.i30.1043225132759
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2011;17(35):3976–3985. doi:10.3748/wjg.v17.i35.397622046085
   PubMed Web of Science ®Google Scholar
• Li C, Zou J, Zheng G, et al. MiR-30a Decreases Multidrug Resistance (MDR) of gastric cancer cells. Med Sci Monit. 2016;22:4509.
   PubMed Web of Science ®Google Scholar
• Wang Z, Qiao Q, Chen M, et al. miR-625 down-regulation promotes proliferation and invasion in esophageal cancer by targeting Sox2. FEBS Lett. 2014;588(6):915–921. doi:10.1016/j.febslet.2014.01.03524508466
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang CZ, Lu SX, et al. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene. 2015;34(8):965–977. doi:10.1038/onc.2014.3524632613
   PubMed Web of Science ®Google Scholar
• Zhang H, Feng C, Zhang M, et al. miR-625-5p/PKM2 negatively regulates melanoma glycolysis state. J Cell Biochem. 2019;120(3):2964–2972. doi:10.1002/jcb.2691730500994
   PubMed Web of Science ®Google Scholar
• Wu Q, Yang Z, Xia L, et al. Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget. 2014;5(22):11552–11563. doi:10.18632/oncotarget.259425344911
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang J, Zhang J, et al. MicroRNA-625 inhibits the proliferation and increases the chemosensitivity of glioma by directly targeting AKT2. Am J Cancer Res. 2017;7(9):1835–1849.28979807
   PubMed Web of Science ®Google Scholar
• Jiang Q, Lu X, Huang P, et al. Expression of miR-652-3p and effect on apoptosis and drug sensitivity in pediatric acute lymphoblastic leukemia. Biomed Res Int. 2018;2018:5724686. doi:10.1155/2018/572468629967774
   PubMed Web of Science ®Google Scholar
• Duong HQ, Hwang JS, Kim HJ, et al. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. Int J Oncol. 2012;41(3):855–861. doi:10.3892/ijo.2012.151622710732
   PubMed Web of Science ®Google Scholar
• Schafer A, Teufel J, Ringel F, et al. Aldehyde dehydrogenase 1A1–a new mediator of resistance to temozolomide in glioblastoma. Neuro-Oncology. 2012;14(12):1452–1464. doi:10.1093/neuonc/nos27023132408
   PubMed Web of Science ®Google Scholar
• Jiang J, Liu Y, Tang Y, et al. ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway. Onco Targets Ther. 2016;9:5349–5360. doi:10.2147/OTT.S10795727621650
   PubMed Web of Science ®Google Scholar
• Januchowski R, Wojtowicz K, Sterzyska K, et al. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines. Int J Biochem Cell Biol. 2016;78:248–259. doi:10.1016/j.biocel.2016.07.01727443528
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhou W, Xia J, et al. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget. 2014;5(23):11986–11997. doi:10.18632/oncotarget.238825230277
   PubMedGoogle Scholar